Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

(TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme A and response to atorvastatin in coronary artery disease patients.

Basic & clinical pharmacology & toxicology - 1 Mar 2009

Noriega Viviana, Pennanen Christian, Sánchez María Pilar, Chiong Mario, Llancaqueo Marcelo, Lavandero Sergio, Prieto Juan Carlos

Abstract excerpt

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors have been used clinically for lowering total and low-density lipoprotein cholesterol. Interindividual pharmacological differences observed with this treatment have been attributed to genetic differences. The aim of this study was to asses...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atorvastatin
Share to C-Reactive Protein
Share to Cholesterol, LDL

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heptanoic Acids

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hydroxymethylglutaryl CoA Reductases

Share to Pyrroles

Share to Trinucleotide Repeats

Source

Identifiers

PMID: 19067673
DOI: 10.1111/j.1742-7843.2008.00341.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19067673-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

(TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme A and response to atorvastatin in coronary artery disease patients.PMID 19067673Read ↗

(TTA)n repeat polymorphism in the HMG-CoA reductase gene and cholesterolaemia.Semantic proximity Read ↗

Apo A-I promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy.Semantic proximity Read ↗

The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.Semantic proximity Read ↗

Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population.Semantic proximity Read ↗

Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia.Semantic proximity Read ↗

CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia.Semantic proximity Read ↗

The -323Ins10 polymorphism for factor VII is not associated with coronary atherosclerosis in symptomatic men. The REGRESS study group.Semantic proximity Read ↗

Lipid-lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia.Semantic proximity Read ↗

Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy.Semantic proximity Read ↗

Typing of the 3' hypervariable region of the apolipoprotein B gene: approaches, pitfalls, and applications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.